Unhappy With GDUFA II? Note It For GDUFA III, FDA Says
Executive Summary
US agency says it is implementing generic drug user fee program as outlined in commitment letter and any changes should be discussed at negotiations for the 2022 renewal.
You may also be interested in...
GDUFA III: How Much Of A Fee Increase Can Industry Stomach?
Amid questions about generic industry market dynamics, the user fee renewal could focus on limiting increases in US FDA collections.
US Complex Generics Need New Communication Channels
US FDA and complex generic sponsors need a way to talk about reference product and other changes once the pre-submission meetings pathway is exhausted.
Complex Generics May Need New Communications Options In GDUFA III
US FDA and complex generic sponsors need a way to talk about reference product and other changes once the pre-submission meetings pathway is exhausted.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: